Friday, October 23 – U.S. is poised to issue a proposed rule that would subject outbound licensing deals with Chinese biotech companies to additional scrutiny

Friday, October 23 – As telehealth promotes GLP-1s for addiction, experts worry about fragmented care, and exposing patients to unknown risks.

Thursday, October 22 – Ozempic plus hormone therapy may help boost weight loss at menopause.

Thursday, October 22 – For patients with nonarteritic anterior ischemic optic neuropathy (NAION), glucagon-like peptide-1 (GLP-1) receptor agonist exposure is associated with earlier sequential NAION, according to a study presented at the annual meeting of the American Academy of Ophthalmology, held Oct. 9 to 12 in New Orleans.

Thursday, October 22 – Crude odds ratios suggest an increased risk for age-related macular degeneration (AMD) in association with glucagon-like peptide-1 receptor agonist (GLP-1 RA) use, but this finding is reversed after adjustment for cardiometabolic confounding variables, according to a study presented at the annual meeting of the American Academy of Ophthalmology, held Oct. 9 to 12 in New Orleans.

Thursday, October 22 – (MedPage Today) — A single, 10-minute transcranial ultrasound session led to a modest but significant drop in delusion scores among people with schizophrenia in a sham-controlled pilot trial. (npj Acoustics)
President Trump announced that the…

Thursday, October 22 – Around half a million Australians use GLP-1 medications for diabetes—and when you add people who use them for obesity and weight-related conditions, the total is much higher.

Thursday, October 22 – (MedPage Today) — Treatment with the novel triple agonist retatrutide improved obstructive sleep apnea (OSA) in adults with obesity or overweight regardless of type 2 diabetes, two parallel randomized clinical trials showed.
Mean reduction in…

Wednesday, October 21 – Post hoc analyses in women divided by menopausal status show how Novo’s next-generation GLP-1 drug affects key cohorts of patients.

Wednesday, October 21 – (MedPage Today) — Roughly a quarter of active-duty U.S. Army men had a single morning testosterone concentration under 300 ng/dL, a commonly used cutoff for low testosterone. (JAMA)
Nearly half of American women ages 40 to 60 reported menopausal…

Wednesday, October 21 – The success stories of GLP-1 weight-loss medications are dominating the airwaves. Midlife women, who commonly experience weight gain resulting from menopause, have been especially drawn to the drugs.

Tuesday, October 20 – Mayo Clinic researchers found that GLP-1 receptor agonists, medications widely used for diabetes and weight management, were associated with a lower risk of dialysis or kidney transplantation in adults with bipolar disorder and chronic kidney disease.

Tuesday, October 20 – While GLP-1 medicines have become synonymous with weight loss, at least one expert thinks amylin would have been the go-to target if biopharma had been focused on the blockbuster indication 10 years ago. A new wave of therapies is now exploring this potentially gentler mechanism.

Monday, October 19 – GLP-1 medications, widely prescribed for diabetes and weight loss, may also help protect people from serious complications after surgery. People taking GLP-1 medications had lower rates of major heart-related complications and infections after surgery than those not taking the drugs, according to results of a study of more than 2 million adults undergoing surgery presented at the ANESTHESIOLOGY 2026 annual meeting.

Saturday, October 17 – Retatrutide, a next-generation GLP-1 weight-loss drug, is not yet approved for use. Nevertheless, online forums reveal that people are purchasing unapproved versions of the drug, which are not intended for human consumption, and sharing their experiences.

Friday, October 16 – Treatment with glucagon-like peptide-1 receptor agonists (GLP-1s) was associated with lower risks of psychiatric hospitalization and psychiatric emergency department visits in people with both schizophrenia and type 2 diabetes (T2D), compared with no GLP-1 treatment or treatment with newer diabetes medications, according to new research published in The Lancet Psychiatry.

Friday, October 16 – Popular diabetes and weight loss drugs such as Ozempic and Wegovy have been linked to a slightly increased risk of a rare condition that can cause sudden, potentially permanent vision loss. Although the risk remains very low, Rutgers researchers say the findings warrant attention as millions of people turn to GLP-1 medications.

Thursday, October 15 – Trial finds 2 strategies to maintain weight loss results after stopping GLP-1s.

Thursday, October 15 – The candidate is an oral version of ecnoglutide, a subcutaneous formulation of which is approved in China for type 2 diabetes and weight management. Pfizer owns commercialization rights for ecnoglutide in the Asian country.

Thursday, October 15 – A wave of clinical trials have begun to test the ability of GLP-1 weight loss drugs to quell various substance use disorders, with some promising results. A new trial announced…

Thursday, October 15 – Doctors suggest digestive aids, protein supplements, skin care and more.

Wednesday, October 14 – Orforglipron shows weight loss benefits for both menopause and type 2 diabetes

Thursday, October 15 – (MedPage Today) — Two recent deaths tied to counterfeit versions of retatrutide, an investigational weight-loss medication, were reported to the FDA. (CBS News)
Meanwhile, ongoing lawsuits allege that GLP-1 receptor agonists can cause severe…

Wednesday, October 14 – (MedPage Today) — NEW ORLEANS — GLP-1 receptor agonists did not significantly affect anti-VEGF treatment frequency in patients with diabetic macular edema (DME), a large retrospective cohort study showed.
Over 24 months of follow-up, “no sustained…

Wednesday, October 14 – A recent Phase III clinical trial, TRIUMPH-2, evaluated the efficacy and safety of retatrutide, a triple receptor agonist and experimental once-weekly injection being developed to treat obesity and type 2 diabetes. What sets it apart from drugs such as semaglutide (Wegovy), which targets one hormone, and tirzepatide (Zepbound), which targets two, is its ability to activate three hormone receptors at once.

Sunday, October 11 – Recent research shows that structured support may help with weight maintenance after stopping GLP-1s. licensed miniseries · E+/Getty

Most people regain a significant portion of the weight they lost within 1 year of stopping GLP-1 medications such as semaglutide (Wegovy) or tirzepatide (Zepbound).

A small study found that structured support, including a digital weight management app or medically tailored meals, may help slow weight regain after stopping GLP-1 medications.

Saturday, October 10 – HHS is cranking up its efforts to accelerate drug development; more reports are emerging about off target effects of obesity drugs. 

Saturday, July 4 – On June 16, 2026, the US Food and Drug Administration (FDA) issued 25 warning letters to various telehealth companies alleging that their websites contained false or misleading claims about compounded semaglutide, tirzepatide, and, in one case, liraglutide products….By: McDermott Will & Schulte

Tuesday, May 19 – Semaglutide for Weight Loss Without Diabetes: What the Approval Covers, What Programs Skip, and What Results Actually Look Like